NCT01675011终止不适用
Safety and Efficacy of Embozene Microspheres for Uterine Fibroid Embolization Compared to Embosphere for Symptomatic Relief From Uterine Fibroids
适应症
试验速览
- 阶段
- 不适用
- 状态
- 终止
- 入组人数
- 4
- 试验地点
- 2
- 主要终点
- Primary Endpoint
研究概览
简要总结
This is a randomized, prospective, multi-center study of 225 female subjects age 30-50 years with symptoms from uterine fibroids. All subjects will be followed for a total of thirty-six (36) months following uterine fibroid embolization.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 30 Years 至 50 Years（Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Subject is able to provide informed consent and must sign the Institutional Review Board approved Informed Consent Form.
- •Pre-menopausal women age 30-50 years at time of enrollment
- •Have been selected forUterine Fibroid Embolization (UFE) prior to entry to the study.
排除标准
- •Patient has a history of pelvic malignancy
- •Patient has an abnormal Pap smear within 12 months of the planned Uterine Fibroid Embolization procedure
- •Patient with coexisting condition that might explain abnormal bleeding (including endometrial hyperplasia and adenomyosis) or pelvic pain (including endometriosis and ovarian cysts).
- •Is at substantial risk for the need of organ transplantation, such as renal insufficiency.
- •Patient has evidence of current or recent pelvic inflammatory disease or uterine infection.
- •Patient with a severe contrast allergy or renal insufficiency that would represent a contradiction to the administration of iodine-based contrast agents.
- •Patients unable to comply with the follow-up requirements of the study.
结局指标
主要结局
Primary Endpoint
时间窗: 12 Months post study procedure
The primary effectiveness endpoint for this clinical trial is the proportion of subjects who have success, defined as 50% menstrual blood loss (MBL) reduction or less than 80 ml of MBL per cycle, evaluated by the Alkaline Hematin (AH) method, at 12 months.
次要结局
未报告次要终点
研究者
研究点 (2)
Loading locations...
相似试验
Unknown
不适用
Safety and Efficacy of Embozene Microspheres for Uterine Fibroid EmbolizationUterine FibroidsNCT02884960Gary Siskin, MD118
Enrolling By Invitation
不适用
Polyvinyl Alcohol Embolization MicrospheresPrimary Liver CancerNCT05770635Shanghai Huihe Medical Technology Co., Ltd224
已完成
不适用
Clinical Trial to Evaluate the Safety and Effectiveness of the IBV® Valve System for the Treatment of Severe EmphysemaEmphysemaCOPDNCT00475007Olympus Corporation of the Americas277
终止
3 期
Efficacy And Safety Of Azithromycin SR Compared With Minocycline In AcneAcne VulgarisNCT00392223Pfizer118
招募中
1 期
Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast CancerHR+/HER2-negative Breast CancerMetastatic Breast CancerNCT05455619SynDevRx, Inc.52